London
· Delayed Price · Currency is GBP · Price in GBXBiVictriX Therapeutics Statistics
Total Valuation
BiVictriX Therapeutics has a market cap or net worth of GBP 8.25 million. The enterprise value is 6.77 million.
| Market Cap | 8.25M |
| Enterprise Value | 6.77M |
Important Dates
The last earnings date was Tuesday, September 17, 2024.
| Earnings Date | Sep 17, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BiVictriX Therapeutics has 82.53 million shares outstanding. The number of shares has increased by 14.81% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 82.53M |
| Shares Change (YoY) | +14.81% |
| Shares Change (QoQ) | -8.25% |
| Owned by Insiders (%) | 14.44% |
| Owned by Institutions (%) | 37.81% |
| Float | 47.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.58 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.53 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.19 |
Financial Position
The company has a current ratio of 4.40, with a Debt / Equity ratio of 8.81.
| Current Ratio | 4.40 |
| Quick Ratio | 4.40 |
| Debt / Equity | 8.81 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.10 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -103.99% and return on invested capital (ROIC) is -70.51%.
| Return on Equity (ROE) | -103.99% |
| Return on Assets (ROA) | -62.99% |
| Return on Capital (ROIC) | -70.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -157,118 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -28.57% |
| 50-Day Moving Average | 10.99 |
| 200-Day Moving Average | 11.32 |
| Relative Strength Index (RSI) | 59.32 |
| Average Volume (20 Days) | 1,101,011 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.24M |
| Pretax Income | -3.21M |
| Net Income | -2.67M |
| EBITDA | -3.17M |
| EBIT | -3.24M |
| Earnings Per Share (EPS) | -0.04 |
Balance Sheet
The company has 1.69 million in cash and 203,000 in debt, giving a net cash position of 1.49 million or 0.02 per share.
| Cash & Cash Equivalents | 1.69M |
| Total Debt | 203,000 |
| Net Cash | 1.49M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 2.31M |
| Book Value Per Share | 0.03 |
| Working Capital | 2.00M |
Cash Flow
In the last 12 months, operating cash flow was -2.27 million and capital expenditures 151,000, giving a free cash flow of -2.12 million.
| Operating Cash Flow | -2.27M |
| Capital Expenditures | 151,000 |
| Free Cash Flow | -2.12M |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BiVictriX Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.81% |
| Shareholder Yield | -14.81% |
| Earnings Yield | -35.21% |
| FCF Yield | -25.71% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |